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Background: The neurotrophins brain-derived neurotrophic factor (BDNF) and neurotrophic factor 3 (NT3) could
play a role in addictive behavior. Interactions between BDNF and dopamine transmission influence the alcohol in-
take. It has been hypothesized that extensive alcohol consumption leads to diminished circulating BDNF levels and
impaired BDNF-mediated protective mechanisms. What is more, alcohol dependency causes changes in lipid
metabolism which in turn may influence the neurotrophin system.
Methods: In this study, we tested the hypothesis that alcohol withdrawal increases the serum levels of BDNF in
alcoholic patients and investigated correlations between serum BDNF and NT3 and alcohol in breath as well as
with the body-mass-index (BMI), lipoprotein profiles and lifestyle factors in 110 male in-patients diagnosed with
alcohol addiction on the first day after admission and at discharge.
Results: The intoxication level (alcohol in breath at admission) was significantly correlated with liver enzymes and
BDNF concentrations (R = .28; p = .004). Patients with positive breath-alcohol test at admission had about 9 times
higher NT3 levels and higher liver enzyme concentration levels than nonintoxicated subjects. Alcohol intoxicated
patients with pathological aspartate aminase (ASAT) levels had even higher NT3 level (F = 5.41; p = .022). The con-
centration of NT3 was positively associated with the (BMI) (admission R = .36; p = .004; discharge R = .33; p = .001),
and the obese patients had 3 to 5 times higher NT3 concentration than the others. Low-density lipoprotein (LDL)
concentration levels were found to positively correlate with NT3 concentration levels (admission R = .025; p = .015
discharge R = .24; p = .23).
Conclusion: Other than expected, the levels of NT3 and to a lesser extent BDNF levels, were found to be
significantly increased in acute alcohol abuse. Alcohol deprivation did not significantly change the serum
neurotrophin levels at admission. NT3 levels were positively correlated with the BMI and LDL levels. Because of
expected difference between genders, we recommend investigating these correlations further in patients of both
genders.
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BDNF is presumably involved in neuroadaption to ad-
dictive behaviour. Interactions between BDNF and the
dopamine transmission may influence the alcohol inges-
tion [1,2]. Extensive alcohol consumption dysregulates
the BDNF-mediated schelter mechanisms resulting in
further increase of alcohol ingestion. The BDNF mRNA
expression in the Striatum Dorsalis depends on the dur-
ation of alcohol abuse. After six weeks of alcohol con-
sumption the BDNF level in the cortex was shown to
decrease, and even after a two-weeks abstinence it did
not normalize. Other studies revealed a region-specific
upregulation of BDNF after alcohol consumption [3].
Huang and colleagues [4] found that BDNF serum con-
centration in alcoholic patients has normalized after just
one-week withdrawal. However, permanent changes in
BDNF signalling could influence the addiction [5]. A de-
creased BDNF-expression or attenuated signal transduc-
tion through the BDNF-receptors in the presence of
alcohol could also contribute to alcohol-induced neuro-
degeneration. Therefore, it has been speculated, that the
administration of BDNF could protect against alcohol
abuse. Additionally, a significant correlation between
serum-BDNF and the number of abstinence days was
also described. As a result, BDNF could be used as a
biomarker for abstinence in addictive patients. In sub-
jects with a family history of alcohol abuse over several
generations, an interaction was detected between allele
variants of BDNF genes associated with increased
volumes of brain gray substance and the addictive
behaviour [6]. Furthermore, the comorbid psychiatric
diseases and their influence on developing alcohol
dependency could be of interest [3].
BDNF also plays a role in sleep disturbances associated
with alcohol abuse. Since BDNF plays an important
role in the glutamate/light/induced phase-change [7],
alcohol-associated sleep disturbances that are deter-
mined by glutamate-induced phase shifts of the circa-
dian rhythm can be attenuated by increasing the BDNF
levels.
But not only psychical influences and the severity or
form of alcohol abuse may be important for the neuro-
trophin expression, but also the metabolic status: for
example, BDNF concentrations were found to be influ-
enced by glucose intolerance in alcoholic patients.
After alcohol abstinence, BDNF levels were signifi-
cantly increased in pre-diabetes mellitus patients, but
not in patients with a normal glucose tolerance or in
diabetic patients [8].
Alcohol misuse has serious effects on the liver metab-
olism and the lipoprotein levels in serum [9]. Correla-
tions between lipoproteins and neurotrophins were also
found in mice treated with cholesterol (Chol) reducing
drugs like statins which increased the hippocampalBDNF levels with a concomitanly antidepressant-like ef-
fect [10]. In patients with angina pectoris, plasma BDNF
was inversely associated with low-density lipoprotein
(LDL) cholesterol levels, and positively associated with
high-density lipoprotein (HDL) cholesterol levels [11].
High dietary cholesterol intake elevated BDNF mRNA
expression in mice [12]. In young men, serum BDNF
was positively correlated with body mass index and total
cholesterol [13]. Since the benefits of the omega-3 poly-
unsaturated fatty acids (omega-3 PUFA) found in fish
oils may be attributed to a number of distinct biological
effects on lipoprotein metabolism like the reduction
of triglycerides and the possible reduction of pro-
atherogenic small dense LDL particles (sdLDL) [14], it is
possible that the dietary intake of fish also affects the
neurotrophin levels.
We are not aware of publications about the influence
of ethanol on NT3 concentrations in serum. However, in
one study it was reported that the exposition to ethanol
did not influence the NT3 mRNA expression in the
brains of rat pups [15]. In another study done on cul-
tured cortical neurons, NT3 treatment did not attenuate
the toxic effect of ethanol [16]. Others found elevated
NT3 levels in different brain areas of juvenile rats
prenatally exposed to alcohol [17].
In this study, we investigated correlations between
serum BDNF and NT3 with alcohol in breath at admis-
sion as well as body-mass-index, lipoprotein profile and
lifestyle factors in 110 male in-patients diagnosed with
alcohol addiction on the first day after admission and at
discharge. After detoxification, we expected an increase
in the serum concentration of BDNF and NT3 [18,19].
Methods
Ethics
This study was approved by the Institutional Review
Boards of the University of Medicine the Rostock. All
subjects provided formal consent before being examined
and were compensated up to 50 EURO.
Subjects
The patients were volunteers for alcohol detoxification
treatment in the psychiatric University Hospital. A total
of 110 alcoholic male patients were enrolled with mean
age of 44.5 ± 9.8 years and BMI 24.5 ± 3.8. BMI was cal-
culated according to the formula Weight (kg)/Height
(m)2. Alcohol addiction was judged by symptoms of
alcohol withdrawal severe enough to require pharmaco-
logic treatment. Exclusion criteria included a history of
other psychiatric disorders than alcohol abuse, neuro-
logical illness, current or unstable medical illnesses or
disability. Individuals on any kind of ongoing vitamin
substitution were also excluded from the study. All pa-
tients were free of psychiatric medication at the time of
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mination. Demographic characteristics of the partici-
pants are shown in Table 1.
Alcohol consumption and biochemical analysis
The average alcohol consumption (1 alcohol unit = 20 g
alcohol/d) and the duration of alcohol abuse were assessed
(Table 1). For fatty acid and liver enzymes Gamma-
glutamyltransferase (GGT) and Alanine-Aminotransferase
(ALAT) and Aspartate-Aminotransferase (ASAT) analysis a
blood sample was drawn from the alcoholic patients at the
morning after hospital admission and after the detoxifica-
tion, at the day of discharge from the hospital. Additionally,
serum levels of the brain-derived neurotrophic factor
(BDNF) and neurotrophic factor-3 (NT3) were also mea-
sured. As a criterion of the severity of alcohol disease, we
recorded the liver enzymes ASAT, ALAT and GGTand cal-
culated their influence on the neurotrophin and lipoprotein
levels.
Analytical methods
BDNF and NT3 were analysed using ELISA test kits
from Ray Bio®. The level of total cholesterol (Chol) and
the HDL and LDL lipoproteins were analysed using a kit
from AXONLAB ® run on the Cobas Fara Analyzer
(Roche, Switzerland). Liver enzymes ASAT, ALAT and
GGT were measured as previously described [20].
Statistical methods
Mean scores and standard deviation were reported from
continuous variables; absolute and relative frequencies
were described for categorical data. Paired-sample t-test
was used to test for differences between the two assess-
ments of the biochemical analysed concentrations.
Spearman rank correlations were applied to test for
relation between continuous variables, because most of
them were found not to be normally distributed (by
Kolmogorov-Smirnov-test). To test for relation between
categorical and continuous variables, one-way analysis ofTable 1 Case demographics
N Mean ± SD
Age [years] 110 44.76 ± 9.55
Body-mass-index 109 24.46 ± 3.75
Days between assessments 106 10.83 ± 2.44
Daily alcohol consumption 104 30 U ± 10
Years of addiction 104 9.30 ± 6.64
% Frequency of fish meals/week
Never 14 12.8
<2 weekly 83 76.1
≥2 weekly 12 11.0
Smoker 100 91.7variance (ANOVA) was applied. The significance level
for all tests was set at p < 0.05. Because of the explorative
nature of our study, we did not correct the level of sig-
nificance of our findings for multiple testing. Data were




The patients were 44.76 ± 9.55 years old (ranging from
18 to 67 years) and had a history of alcohol addiction of
9.30 ± 6.64 years (ranging from 1 to 31 years). 32 pa-
tients showed up at admission with negative breath-
alcohol test (29.1%). The BMI of the participants was
24.46 ± 3.75 (ranging from 16 to 35). The time difference
between the both assessments was, on average, 10.83 ±
2.44 days (ranging from 4 to 16 days). The vast majority
of the alcohol dependent patients reported to eat fish
two times a week (76.1%); none of them was a vegetar-
ian; 91.7% were smokers (Table 1).
The frequency of pathologically high concentration of
various liver enzymes was as follows: ASAT – n = 62
(56.4 ALAT – n = 54 (49.1%), and GGT – n = 81
(73.4%). Only seven patients (6.4%) could be classified as
suffering from a mild dependence on alcohol based on
the criterion of having no pathologically elevated liver
enzyme and showing-up at admission with negative
breath-alcohol test versus either showing at least one
pathologically elevated liver enzyme or showing positive
breath alcohol levels at the time of admission. As might
have been expected, these two groups did not differ in
any of the analysed lipoproteins, neurotrophins or liver
enzymes concentration in serum because of the very
small number of ‘mildly dependent’ patients (Table 2).
Socio-demographic and illness-related variables in rela-
tion to neurotrophins, lipoproteins, and liver enzymes
The age of the subjects was significantly correlated with
ASAT and GGT concentration in the blood and showed
a tendency for an association with BDNF at both assess-
ments. The alcohol breath concentration was signifi-
cantly correlated with ASAT and ALAT levels in blood
and with BDNF concentration at admission. There was
no significant correlation between age, alcohol in breath
and lipoproteins or NT3 concentration in blood at both
assessments (Table 3).
The BMI was significantly associated with the NT3
concentration at both assessments (admission: R = 0.36;
p = 0.004); discharge: R = 0.33; p = 0.001) with the group
of obese patients (n = 10; BMI > 30) having, on average,
three to five times higher NT3 concentration than the
others; as well as with the HDL concentration at
admission (admission: R = −0.33; p <0.001). It did
not, however, correlate with the HDL concentration at
Table 2 Comparison of parameter concentration between admission and discharge (paired-sample t-test)
N Admission Discharge Reference T Df P
BDNF [ng/ml] 104 183.97 ± 92.07 173.38 ± 96.07 1.16 99 0.249
NT3 [pg/ml] 93 262.51 ± 695.91 263.67 ± 674.51 −0.24 87 0.808
HDL [mmol/L] 107 2.35 ± 0.99 1.69 ± 0.52 1.1-2.3 mmol/L 7.24 106 < 0.001
LDL [mmol/L] 110 3.29 ± 1.22 3.41 ± 1.15 <3 mmol/L −0.90 107 0.369
Cholesterol, total 109 6.60 ± 1.65 5.83 ± 1.59 <6 mmol/L 4.72 106 < 0.001
ASAT [U/L] 110 93.55 ± 91.03 <50 U/L
ALAT [U/L] 110 72.13 ± 63.16 <50 U/L
GGT [U/L] 110 284.51 ± 444.48 <60 U/L
Breath alcohol 110 1.20 ± 1.11
[‰]
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enzyme or lipoprotein concentration.
The longer the period of inpatient treatment, the
higher the BDNF concentration at admission (R = 0.20;
p = 0.042); the lower the NT3 concentration (admission:
R = −0.45; p < 0.001; discharge: R = −0.46; p < 0.001); and
the lower the breath alcohol concentration (R = −0.22;
p = 0.021). It is worth mentioning that the period of in-
patient treatment depends on the one hand on the pa-
tient’s motivation to undergo the therapy and to take
part in the psychotherapeutic program, on the other
hand, on the severity of the withdrawal syndrom. The
patients with the lower breath alcohol concentration on
admission could have been stronger motivated for the
therapy, since they already had reduced their alcohol
intake prior to admission, therefore they completed the
full-length therapy program. Still, the same patients
could also experience more severe withdrawal symptoms
because of their attempt at withdrawal without support-
ing medication, also resulting in a longer inpatient treat-
ment. The patients with negative breath-alcohol test at
admission had about nine times lower NT3 concentra-
tion both at admission (F = 3.75; p = 0.056) and at
discharge (F = 4.64; p = 0.034; as well as lower ASAT
(F = 16.03; p < 0.001) and ALAT concentration (F = 7.01;
P = 0.009).
As expected, the more alcohol units the patients
reported to drink per day, the higher was the HDL con-
centration at discharge (R = 0.27; p = 0.006). Likewise theTable 3 Correlations of age and breath alcohol with
selected neurotrophin and liver enzyme concentrations
Age [years] Breath alcohol [‰]
BDNF admission −0.17 (0.095) 0.28 (0.004)
BDNF discharge −0.18 (0.077) 0.03 (0.737)
ASAT 0.23 (0.016) 0.43 (<0.001)
ALAT 0.07 (0.495) 0.28 (0.003)
GGT 0.27 (0.004) 0.06 (0.549)HDL concentration at discharge correlated with the
duration of treatment (R = 0.24; p = 0.015) and the num-
ber of years of alcohol dependence (R = 0.21; p = 0.036).
Smokers had a tendency of lower NT3 concentration
compared to non-smokers at both assessments (admission:
F = 3.84; p = 0.53; discharge: F = 3.60; p = 0.061). Smoking
was not related to any patient-related background variables
or to other neurotrophins and lipoproteins, or liver enzyme
concentrations in our investigation. The presence of fish in
the diet was unrelated to all assessed parameters and
variables (Table 2).
Liver enzymes, neurotrophins and lipoproteins
The higher the LDL concentration in blood serum was,
the higher was the NT3 concentration at admission
(R = 0.25; p = 0.015) and at discharge (R = 0.24; p =
0.023). There was no further substantial association be-
tween any lipoproteins and liver enzymes concentration
or BDNF concentration in the patients. However, the pa-
tients with the pathologically high ASAT concentration
showed higher NT3 concentration at admission (F =
5.41; p = 0.022) than those with the normal ASAT con-
centration. This was the only difference in the lipopro-
teins and neurotrophin concentrations found between
the patients with one pathologically elevated liver en-
zyme and those with normal enzyme concentrations
(Table 2).
Changes in lipoproteins and neurotrophin levels between
admission and discharge
There was no significant difference in the neurothropin
concentrations at admission and at discharge. The HDL
and the total cholesterol concentration were found sig-
nificantly reduced at discharge as compared to those at
admission (Table 2). Seven percent of the variance in the
NT3 concentration at discharge could be explained by
the variance in the lipoproteins and liver enzymes in a
multiple regression with HDL concentration being the
only significant variable in the regression equation
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ation in BDNF concentration however could not be
caused by the same mechanism. The regression models
with concentration of the various lipoproteins at dis-
charge as dependent variables and the neurotrophins
combined with the liver enzymes from admission as
independent variables were all not significant.
Discussion
It has been reported that in alcohol dependent subjects,
serum BDNF-concentration recovers after alcohol
deprivation [18,19]. In our study done on 110 alcohol-
intoxicated patients we could not confirm this finding.
On the contrary we found that alcohol deprivation did
not significantly change the elevated serum neurotro-
phin levels at admission. In this study, we show in a rep-
resentative number of subjects, significant correlations
between the NT3 concentrations and the BMI index,
LDL levels and liver enzyme concentrations at admis-
sion. This points to a possible biological association be-
tween the neurotrophins and lipoproteins concentration
levels in alcoholic patients, which both could be clinic-
ally useful biochemical markers in addition to usual
laboratory parameters.
Only few and inconsistent results on BDNF, NT3 and
lipoprotein concentrations in alcohol dependent patients
have been published by now. Zanardini et al. reported a
significant reduction in BDNF serum levels in alcohol-
dependent patients as compared to healthy subjects [21].
Also binge drinking results in attenuated BDNF levels in
humans [22]. In vitro, long-term chronic ethanol expos-
ure results in reduced BDNF signalling in human neuro-
blastoma cells [23]. Similar results were described in
animal models, with reduced hippocampal neurotrophin
content [24] and reduced BDNF gene expression [25] in
rats after long-term chronic ethanol consumption. Even
a short-term exposure to ethanol resulted in a decreased
BDNF mRNA expression in the mouse cerebellum [26].
Additionally, ethanol was found to block the BDNF
enhancement of postsynaptic NMDA receptors [27] in
mice. Other animal study showed that ethanol neuro-
toxicity may be ameliorated by supplementing with
neurotrophic factors [28].
But there are other animal studies relating a quite
opposite view on the interaction between ethanol and
neurotrophins: Bruns & Miller [29] reported that ethanol
increased the number of NGF- and BDNF-expressing
neurons and the neurotrophin content per somata in the
cerebral cortex of the adult rat. However, after an epi-
sodic exposure to ethanol the BDNF content increased
and the NT3 levels decreased in the parietal cortex while
in the hippocampus the amounts of both neurotrophins
increased. Neurotrophin content in the rat basal fore-
brain was differentially affected by episodic exposure toethanol: NGF and NT-3 content in the basal forebrain
was reduced and NGF and BDNF content in the septal
nuclei was increased [30].
Prenatal alcohol exposure in rats increased BDNF expres-
sion in the frontal cortex, while environmental enrichment
resulted, on the contrary, in lowered BDNF [17]. In mice,
the injections of BDNF and NT3 could modulate neuroa-
daptation to ethanol, potentially influencing the function of
postmitotic neurons in the adult brain [31].
It is known that BDNF plays a role in energy metabol-
ism and body weight regulation in humans [32]. Choles-
terol and lipoproteins have important functions as
structural components of cellular membranes (including
neurons) and as precursors of a variety of hormones. A
number of studies revealed the association between the
plasma [11] and serum [13] BDNF levels and the lipo-
proteins. Therefore, dietary lipids may impact different
pathological processes, possibly in connection with
neurotrophic factors.
Weak points of this study are the lacking of a com-
parison group (ie, nonalcoholic subjects) and the limita-
tion to male subjects only. Another limitation of the
study is that 90% of the recruited patients were smokers.
There are several studies relating neurotrophins expres-
sion in endothelial cells in the airways with smoking
[33]. However, the experimental evidence relating smok-
ing to serum BDNF level is controversial with some
studies reporting decreased BDNF levels in the serum
[34] and plasma [35,36] of smokers and two studies
reporting higher serum BDNF levels in smokers than in
non–smokers [22,37]. Further, a recent report showed
that dietay fish oil increased BDNF levels in the rat
hippocampus [38]. For this reason we cannot exclude
that the admission levels of BDNF could have been influ-
enced by the dietary omega-3 polyunsaturated fatty acids
levels in those patients having more than two fish meals
per week.Conclusions
To our knowledge, a correlation between lipoprotein
metabolism and neurotrophins in alcoholic men may
provide a deeper insight into the broad field of alcohol-
induced changes in neuroactive substances. Because of
the expected gender-related differences, further studies
are required to test the correlation between neurotro-
phins and lipids in women with alcohol diseases [32].Availability of supporting data
Supporting data is available upon request form the
corresponding author.
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